China is intensifying scrutiny of illegal kickbacks paid by pharmaceutical companies as part of efforts to drive down drug prices, analysts say, as it rolls out a plan to audit 77 drugmakers across the country.
The Ministry of Finance announced (link in Chinese) Tuesday a list of 77 drugmakers that had been “randomly selected” for auditing in June and July. The list includes the local arms of three multinationals: Sanofi, Eli Lilly & Co. and Bristol-Myers Squibb Co. Also listed are some of China’s biggest domestic players, including Shanghai Fosun Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Pharmaceuticals Holding Co. Ltd.
京公网安备 11010502034662号 